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Abstract The multidrug resistance protein (MRP) is an ATP-
dependent transport protein for organic anions, as well as neutral 
or positively charged anticancer agents. In this study we report 
that dinitrophenyl-S'-glutathione increases ATPase activity 
in plasma membrane vesicles prepared from the MRP-over-
expressing cell line GLC4/ADR. This ATPase stimulation 
parallels the uptake of DNP-SG in these vesicles. We also show 
that the (iso)flavonoids genistein, kaempferol and flavopiridol 
stimulate the ATPase activity of GLC4/ADR membranes, 
whereas genistin has no effect. The present data are consistent 
with the hypothesis that certain (iso)flavonoids affect MRP-
mediated transport of anticancer drugs by a direct interaction 
with MRP. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
A major problem in the treatment of cancer is the occur-
rence of cellular resistance to cytotoxic drugs. Cancer cells can 
be simultaneously resistant to a wide spectrum of natural 
agents, such as anthracyclines and vinca alkaloids. One 
form of resistance is caused by overexpression of the drug 
transporter P-glycoprotein (Pgp), which belongs to the super-
family of ATP binding cassette (ABC) transporter proteins [1]. 
Characteristic of these proteins are their nucleotide bindings 
domains (NBD), which are essential for ATP binding and 
hydrolysis. Another ABC transporter causing multidrug re-
sistance (MDR) is the multidrug resistance protein (MRP), 
which has been cloned from a drug-resistant small-cell lung 
cancer line [2]. MRP appears to mediate the transport of a 
broad range of drugs across cellular membranes. On the one 
hand, it was concluded from the increased cellular drug efflux 
from MRP-overexpressing or transfected tumour cell lines 
that MRP functions as a transporter of the typical 'MDR' 
anticancer agents [3,4]. On the other hand, the observation 
that the efflux of anticancer drugs from MRP-overexpressing 
cells was glutathione-dependent [5,6] suggested that MRP is a 
transporter of anionic compounds and/or glutathione-conju-
gated drugs [7,8]. Important evidence for the identification of 
MRP as a transporter of multiple organic anions (MOAT) 
came from experiments showing ATP-dependent uptake of 
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glutathione conjugates, such as leukotriene C4, into inside-
out plasma membrane vesicles prepared from MRP-overex-
pressing cells [7,9]. 
In recent years much effort has been directed at the identi-
fication of transport-modulating agents in order to circumvent 
Pgp- and MRP-mediated drug resistance. Among others, sev-
eral members of one group of natural compounds, the so-
called (iso)flavonoids, were found to be able to modulate 
Pgp- and MRP-mediated drug transport in tumour cell lines 
[10,11]. These compounds are important constituents of our 
daily food, since they are metabolic products of many plant 
species, such as vegetables, red wine and tea [12]. Several bio-
logically important activities of (iso)flavonoids are phospho-
tyrosine kinase inhibition [13-15], topoisomerase II inhibition 
[16], and radical scavenging [17,18]. The (iso)flavonoid genis-
tein was shown to inhibit the efflux of daunorubicin from 
small-cell lung cancer GLC4/ADR cells [11] in a competitive 
way [19], although it was not investigated whether genistein 
itself was transported by MRP. Recently a competitive inhibi-
tion of daunorubicin transport by genistein was also shown, 
using plasma membrane vesicles from the MRP-transfected 
NIH3T3 cells [20]. Because of broad interest in (iso)fiavo-
noids, more insight into the interaction of these compounds 
with MRP is important. 
In the present work we have used plasma membrane 
vesicles prepared from GLC4/ADR cells to demonstrate that 
the transport of the MRP substrate dinitrophenyl-S'-gluta-
thione (DNP-SG) into these vesicles is associated with an 
increase in ATPase activity. Subsequently, we show that the 
MRP-related ATPase activity is stimulated by several (iso)fla-
vonoids. 
2. Materials and methods 
2.1. Chemicals 
[3H]GSH was purchased from New England Nuclear (Dreieich, 
Germany). Dithiothreitol (Sigma, St. Louis, MO) was separated 
from [3H]GSH according to Butler et al. [21]. [3H]DNP-SG was 
synthesised as described earlier [23]. l-Chloro-2,4-dinitrobenzene 
(CDNB) was from Sigma (St. Louis, MO). The flavonoid kaempferol, 
the isoflavonoid genistin, malachite green base, ammonium mo-
lybdate, Triton N101, benzbromarone and ATP were from Sigma 
(St. Louis, MO). The isoflavonoid genistein was from ICN Biomed-
icals (Zoetermeer, The Netherlands). The synthetic flavone derivative 
flavopiridol (L86-8275) (—)c«-5,7-dihydroxy-2-(2-chlorophenyl)-8-
[4-(3-hydroxy-l-methyl)-piperidinyl]-4H-benzopyran-4-one was kindly 
provided by Dr. Sedlacek and Dr. Czech (Behringwerke A.G., Mar-
burg, Germany). The (iso)flavonoids were dissolved as a stock solu-
tion of 40 mM in DMSO (Across Chimica, Belgium) and stored at 
-20°C. Before experiments 1:1 dilutions were made in ethanol, fol-
lowed by a dilution in ethanol/water (1:3, v/v) to the appropriate 
concentrations. The maximal concentration of DMSO and ethanol 
was 0.5% (v/v), which was also added in the controls. Membrane 
filters OE67 were from Schleicher and Schuell (Dassel, Germany). 
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Vinblastine was from Eli Lilly Nederland B.V. (Nieuwegein, The 
Netherlands). Doxorubicine hydrochloride was from Laboratoire 
Roger Bellon (France). 
2.2. Cells 
The human small-cell lung cancer cell line GLC4 and its adriamy-
cin-selected MRP-overexpressing subline GLC4/ADR [22] were cul-
tured in RPMI medium (Flow Labs., Irvine, Scotland, UK), supple-
mented with 7.5% fetal calf serum (Gibco, Paisley, UK). GLQ/ADR 
were cultured in the presence of 1.2 uM doxorubicin until 7-14 days 
before experiments. 
2.3. Plasma membrane vesicles 
Plasma membrane vesicles were prepared from parental GLC4 and 
drug-resistant GLC4/ADR cells as described [23]. Cells were harvested 
by centrifugation (275 Xg, 5 min) and washed twice in phosphate-
buffered saline. Subsequently, the cells were incubated in 100 mM 
KC1, 5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride and 
50 mM HEPES/KOH (pH 7.4) for 1 h at 0°C, in order to allow the 
cells to swell. Then the cells were ultrasonicated at 20% of the max-
imum power of an MSE sonicator, Soniprep 150, for 3 bursts of 15 s. 
The suspension was centrifuged (1500Xg, 10 min). The post-nuclear 
supernatant was layered on top of a 46% sucrose cushion. After cen-
trifugation (lOOOOOXg, 60 min) the interface was removed and 
washed in 100 mM KCl/50 mM HEPES/5 mM MgCl2 buffer 
(pH 7.4). The final membrane preparations were stored at —80°C at 
a protein concentration of ~ 4 mg/ml. The enrichment of Na + K + -
ATPase was about 5-fold [23]. 
2.4. Uptake of substrates into vesicles 
Uptake of labelled substrates into vesicles was measured by rapid 
filtration as previously described [24]. Vesicles were incubated in 
KCl/HEPES buffer (pH 7.4) at 37°C (protein concentration 
~0.25 mg/ml), in the presence of 10 mM MgCb with or without 
1 mM ATP and tritium labelled DNP-SG (1.6 KBq/pmol, 32 Bq/ul). 
The reaction was stopped by adding ice-cold KCl/HEPES buffer. 
After rapid filtration, the filters were washed twice with KCl/HEPES 
buffer. Radioactivity on the filters was measured using liquid scintil-
lation counting. 
2.5. ATPase activity determinations 
To measure the rate of ATPase activity in plasma membrane frac-
tions we used a colorimetric method to estimate amounts of inorganic 
phosphate [25] with some modifications. Plasma membranes were in-
cubated in KCl/HEPES buffer (pH 7.4) at 37°C, in the presence of 
1 mM EGTA, 1 mM sodium azide and 0.1 mM ouabain. When in-
dicated, 1 mM ATP was included. Reactions were stopped by addi-
tion of the colour reagent (0.034% w/v malachite green base, 1.05% 
w/v ammonium molybdate and 0.025% v/v Triton N101). After 1 min, 
sodium citrate was added to a final concentration of 3.6% (w/v), in 
order to prevent ATP hydrolysis after having stopped the enzymatic 
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Fig. 1. ATPase activity of GLC4/ADR membranes in time. Phos-
phate production in the presence or absence of DNP-SG is depicted. 
Difference between 10 and 0 uM DNP-SG was also calculated (n). 
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Fig. 2. A: Dose response of DNP-SG-stimulated ATPase activity 
of GLC4 and GLC4/ADR membranes. Incubation t - 60 min. 
ATPase activity at 0 uM DNP-SG was set at 0 nmol/mg/min. Data 
are means ± SD of 5 independent experiments with different 
batches of vesicles. B: Eadie-Hofstee plot calculated from the data 
of (A). 
reaction. Light absorption was measured in an ELISA reader at a 
wavelength of 595 nm. No ATP hydrolysis was seen without the 
addition of membrane vesicles. 
3. Results 
3.1. Transport of DNP-SG into plasma membrane vesicles from 
GLC4 and GLC4IADR cells 
The time dependence of the uptake of [3H]DNP-SG into 
vesicles prepared from GLC4 and GLC4/ADR cells was meas-
ured in the presence or absence of 1 mM ATP. Under these 
conditions the DNP-SG uptake could reach a maximum rate 
of 0.56 ± 0.08 nmol/mg/min in the GLC4/ADR vesicles [23]. In 
contrast, the uptake rate in GLC4 vesicles was very low, con-
sistent with the low MRP expression in these latter cells 
[26,27] and the relatively low uptake of the MRP substrate 
leukotriene C4 in GLC4/ADR vesicles [9]. 
3.2. ATPase activity of MRP 
In order to obtain information on the interaction of (iso)-
flavonoids with MRP we wanted to study their effect on 
MRP-associated ATPase activity. Since MRP-associated AT-
Pase activity, induced by MRP substrates, has not been re-
ported before, we first measured the effect of the established 
MRP substrate DNP-SG on the ATPase activity in GLC4 
and GLC4/ADR plasma membranes. 
346 J.H. Hooijberg et al.lFEBS Letters 413 (1997) 344-348 
Using 1 |0.M of DNP-SG we observed no significant stim-
ulation of the ATPase activity of both GLC4 and GLC4/ 
ADR membranes (data not shown). In contrast, 10 uM 
DNP-SG clearly stimulated the ATPase activity of the 
GLC4/ADR membranes. Fig. 1 shows the time course of 
the phosphate production by GLC4/ADR membranes in the 
presence or in the absence of 10 u,M DNP-SG. 
Subsequently, the substrate concentration dependence of 
the stimulation of the ATPase activity of GLC4 plasma mem-
branes and GLC4/ADR plasma membranes was studied. The 
basal ATPase activity, which was apparently not completely 
blocked by the added inhibitors EGTA, azide and ouabain, as 
shown for GLC4/ADR in Fig. 1, was similar in both cell lines 
(data not shown). Stimulation by DNP-SG was only seen in 
GLC4/ADR membranes (Fig. 2A,B). This stimulation was 
dose-dependent, as shown in Fig. 2A. 
The kinetic parameters of this DNP-SG stimulation of AT-
Pase activity were calculated from an Eadie-Hofstee plot (Fig. 
2B). The apparent KM was 3.9 ±0.8 |J,M, with a maximum 
stimulated phosphate production rate of 6.6 ± 1.2 nmol phos-
phate/mg protein/min. 
We also measured the stimulation of the ATPase activity in 
GLC4/ADR membranes by two other putative MRP sub-
strates. In addition to DNP-SG, oxidised glutathione 
(GSSG) showed a small but significant stimulation of ATPase 
activity in GLC4/ADR membranes. At a concentration of 
100 uM GSSG this stimulation was 10% ±4 (« = 4). In con-
trast, vinblastine did not significantly stimulate the ATPase 
activity in GLC4/ADR membranes. 
3.3. Modulation of the ATPase activity of MRP by 
(iso)flavonoids 
After having shown a DNP-SG stimulatable ATPase activ-
ity in GLC4/ADR membranes, which is consistent with a high 
overexpression of MRP in this cell line and with the ATP-
dependent uptake of DNP-SG in vesicles, we tested the mod-
ulating effects of several (iso)flavonoids on the ATPase activ-
ity of GLC4 and GLC4/ADR membranes. The membranes 
were incubated with one of the (iso)flavonoids kaempferol, 
genistein, genistin or flavopiridol (see Fig. 4), in the absence 
or in the presence of DNP-SG. None of the tested (iso)flavo-
noids affected the ATPase activity of GLC4, shown as an 
example for flavopiridol in Table 2. However, the ATPase 
activity of GLC4/ADR membranes was stimulated signifi-
Table 1 
Effect of genistein on ATPase activity of GLC4/ADR membranes 
Genistein 
(uM) 
0 
10 
50 
100 
150 
200 
0 
10 
50 
100 
150 
200 
Stimulation 
(%) 
0 
5 
6 
9 
9 
11 
23 
30 
35 
35 
40 
36 
P value 
(/ test) 
0 
0.019 
0.029 
0.038 
0.026 
0.025 
0.006* 
0.033 
0.009 
0.004 
0.003 
0.004 
*P value compared to —DNP-SG. Other P values for genistein com-
pared to corresponding value minus genistein. 
Fig. 3. Effect of (iso)flavonoids on the ATPase activity of GLC4/ 
ADR membranes in the presence or absence of 10 |xM DNP-SG. 
Data are means of 5 independent experiments with 5 different 
batches of vesicles. Effects of the (iso)flavonoids were significantly 
different from controls, except for genistin, as calculated with a Stu-
dent's t test (i»<0.05). 
cantly by the (iso)flavonoids kaempferol, genistein and flavo-
piridol, but not by genistin. This stimulation was observed 
whether DNP-SG was present or not (Tables 1 and 2 and 
Fig. 3). 
The specific MRP modulator benzbromarone [28] inhibited 
the DNP-SG-stimulated ATPase activity of GLC4/ADR 
membranes (Table 2). The inhibition of the DNP-SG effect 
(at 10 uM) by 10 |a.M benzbromarone was about 80%. The 
ATPase stimulation by the (iso)flavonoids flavopiridol, genis-
tein and kaempferol, was also inhibited by this compound, as 
is presented for flavopiridol in Table 2. 
4. Discussion 
(Iso)flavonoids are plant polyphenols which are thought to 
be important constituents of our daily food. Estimations of 
the amounts of daily intake vary from milligrams per day [29] 
to 1 g per day [12]. In addition to their antioxidant properties 
[17,18], a number of interesting activities have been described 
for some of these compounds, which may relate to their effects 
on tumour cell proliferation. Among these activities are inhi-
bition of phosphotyrosine kinases, as was shown for e.g. gen-
istein [13-15]. Inhibition of topoisomerase II [16] and protein 
kinase C [30] has also been described. Finally, cyclin-depend-
ent kinases can also be inhibited by certain (iso)flavonoids 
[31-34]. The synthetic flavonoid flavopiridol, for instance, 
showed to be a potent inhibitor of cdc2 kinase activity [32]. 
Of relevance to their use as anticancer agents alone or in 
combination with other agents [34] may be their interaction 
with the drug transporters Pgp and MRP, which are fre-
quently expressed in human tumours [10,11]. 
In this study we have performed an initial analysis of the 
effects of some of the typical members of the large group of 
(iso)flavonoids on MRP activity. We have used isolated plas-
ma membrane vesicles from parental GLC4 cells and from 
drug resistant, MRP-overexpressing GLC4/ADR cells to 
study the transport of MRP substrates, such as DNP-SG 
and GSSG [23]. Since certain (iso)flavonoids are thought to 
interact with ATP-binding sites of their target proteins (e.g. 
topoisomerase II, phospho-tyrosine kinases) we studied puta-
tive effects of these compounds on the MRP-related ATPase 
activity. 
Our results show that the uptake of DNP-SG is ATP-de-
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pendent and is also associated with a stimulation of the AT-
Pase activity in MRP-containing GLC4/ADR vesicles. This 
stimulation followed Michaelis-Menten kinetics. The deter-
mined Fmax for DNP-SG-stimulated ATP hydrolysis was 
6.6 nmol/mg protein/min. In similarly prepared GLC4/ADR 
vesicles, we measured a Fmax for DNP-SG uptake of 
0.56 nmol/mg protein/min. This would imply a ratio of ATP 
hydrolysis per DNP-SG molecule transported of 12:1. In this 
context, two remarks should be made. First, it should be 
mentioned that measurements of the effect of P-glycoprotein 
substrates on Pgp-associated ATPase activity have shown that 
such a quantitative comparison may differ largely between 
studies [35]. Secondly, in our experiments, measurement of 
ATPase activity included all membrane fragments, whereas 
in uptake studies only inside-out vesicles contribute to the 
uptake of DNP-SG. 
Further evidence for the MRP specificity of the DNP-SG-
mediated ATPase activity was the inhibition by benzbromar-
one. This compound has been reported to inhibit MRP-medi-
ated transport of drugs [28]. Finally, the observations that 
oxidised glutathione stimulated ATPase activity of GLC4/ 
ADR membranes, whereas vinblastine (in the absence of 
GSH) did not (see also [36]), were also consistent with MRP 
being an ABC transporter with the transport of organic 
anions coupled to its ATPase activity. 
The stimulating effect of three of the four tested (iso)flavo-
noids (genistein, kaempferol and flavopiridol) on the ATPase 
activity of GLC4/ADR and the inhibition of this effect by 
benzbromarone, gives further evidence that the inhibition of 
MRP-mediated transport of anticancer drugs by these com-
pounds is due to a direct interaction with MRP. Not only the 
inhibition of the ATPase activity, but also the competitive 
inhibition by genistein of daunorubicin efflux [19] supports 
the idea of MRP-mediated transport of certain (iso)flavo-
noids. 
Interestingly, the only isoflavonoid tested here that had no 
effect, i.e. genistin, was shown to have no inhibitory effect on 
daunorubicin transport in MRP-overexpressing tumour cells 
[37]. Although further structure-activity studies are required 
Oil O 
kaempferol OH 0 flavopiridol 
Fig. 4. Structural formulas of the (iso)flavonoids used in this study. 
to explain why genistin has no influence on the ATPase ac-
tivity, the presence of a glucose moiety (see Fig. 4) may play a 
role. 
The fact that the stimulation of the ATPase activity by 
several (iso)flavonoids was seen without addition of GSH or 
DNP-SG, indicates that these compounds do not need to be 
metabolised in order to interact with MRP. Whether the effect 
caused by the (iso)flavonoids in the presence of DNP-SG was 
an additive of DNP-SG and a (iso)flavonoid, or an increase of 
only the (iso)flavonoid-MRP interaction in the presence of 
DNP-SG, is not clear. Therefore, it cannot be excluded that 
the glutathione group of DNP-SG may play a role in the 
action or the transport of the (iso)flavonoids. 
In conclusion, the stimulation of MRP-associated ATPase 
activity by (iso)flavonoids, the inhibition of this effect by 
benzbromarone, as well as the previously described competi-
tive inhibition of daunorubicin transport by genistein [19], 
support the hypothesis that certain (iso)flavonoids interact 
directly with the substrate-binding site of MRP. Future ex-
periments will further elucidate the biochemical mechanism(s) 
of this interaction. 
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Table 2 
Effect of flavopiridol on ATPase activity of GLC4 and GLC4/ADR membranes and its inhibition by benzbromarone 
Cell line ± DNP-SG Flavopiridol 
(LlM) 
Benzbromarone 
(UM) 
% P value 
(t test) 
GLC4 
0 
50 
0 
50 
0 
50 
0 
0 
0 
10 
10 
0 
0 
10 
0 
0.500 
0.457 
0.239 
0.065 
0.300 
0.280 
GLC4/ADR 
50 
0 
50 
0 
50 
0 
50 
0 
50 
10 
0 
0 
10 
10 
0 
0 
10 
10 
6 
0 
11 
6 
0 
23 
37 
10 
7 
0.042 
0 
0.016 
0.004 
0.070 
0.003 
0.015 
0.022 
0.031 
Data are mean percentages of stimulation of 3 independent experiments using different batches of vesicles. Statistical differences between 0 and 
50 |J.M flavopiridol as well as between corresponding values plus (+) and minus (—) benzbromarone are calculated. 
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